rs941798 — PTPN1

Intronic PTPN1 variant tagging a haplotype block associated with reduced insulin sensitivity, higher fasting insulin, and elevated lipids through altered PTP1B expression

See your personal result for PTPN1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Insulin Receptor's Off Switch — and How It Affects Your Metabolic Health

Every time you eat, your pancreas releases insulin, which docks onto the insulin receptor on cell surfaces and triggers a cascade that pulls glucose from your blood into cells for energy. PTP1B11 PTP1B
Protein Tyrosine Phosphatase 1B — the protein encoded by PTPN1 — is the enzyme that turns this signal off by removing phosphate groups from the activated receptor. It acts as a critical brake on insulin signaling: too much PTP1B activity means cells stop responding to insulin faster than they should, effectively causing insulin resistance at the molecular level.

PTP1B also dephosphorylates the leptin receptor, the central hunger-regulating signal. A cell with elevated PTP1B activity is simultaneously less responsive to insulin (glucose handling) and less responsive to leptin (satiety signaling), creating a dual vulnerability to both metabolic disease and weight dysregulation.

The Mechanism

rs941798 sits in an intron of PTPN1 on chromosome 20q13 and does not itself change the PTP1B protein. Instead, it serves as a tag for a haplotype block22 haplotype block
a stretch of DNA inherited together as a unit, typically 50-200 kb, where nearby variants are correlated due to limited historical recombination spanning the entire PTPN1 gene (introns 1-8, ~100 kb) that modulates how much PTP1B is expressed. G-allele carriers appear to produce more PTP1B enzyme, which more aggressively terminates insulin receptor signaling after activation.

The G allele of rs941798 is strongly correlated with rs2426159 (a neighboring intronic SNP) and both tag the same risk haplotype. When researchers tested all SNPs across the PTPN1 locus, the association with metabolic traits was not confined to any single variant but ran across the entire haplotype block — a classic pattern for a regulatory variant whose effect spreads to all SNPs in linkage disequilibrium.

The Evidence

Multiple independent research groups have investigated the PTPN1 intronic haplotype:

Bento et al. (Diabetes, 2004)33 Bento et al. (Diabetes, 2004) typed 23 noncoding PTPN1 SNPs in two independently recruited Caucasian case-control sets. SNPs spanning introns 1-8 were consistently associated with type 2 diabetes across both datasets (p = 0.002–0.038), with odds ratios of approximately 1.3 and a population-attributable risk of 17-20%.

Palmer et al. (Diabetes, 2004)44 Palmer et al. (Diabetes, 2004) in the IRAS Family Study found that all 20 PTPN1 SNPs within the haplotype block were associated with the insulin sensitivity index (Si) in 811 Hispanic Americans (p = 0.003–0.044), with protective haplotypes associated with higher Si (better insulin sensitivity) and risk haplotypes with lower Si and higher fasting glucose.

Cheyssac et al. (BMC Med Genet, 2006)55 Cheyssac et al. (BMC Med Genet, 2006) studied 1,274 French T2D cases and 1,047 controls. rs941798 and the correlated rs2426159 showed "multiple consistent associations" across metabolic traits in 736 normoglycaemic subjects: higher fasting insulin (p = 0.04), higher HOMA-B (p = 0.04), elevated lipid markers (p = 0.02–0.04), and increased systolic blood pressure in risk-allele homozygotes (p = 0.03).

However, the association picture is incomplete. Florez et al. (Diabetes, 2005)66 Florez et al. (Diabetes, 2005) found no significant association between PTPN1 tag SNPs or haplotypes and T2D in 7,883 subjects — the largest study to date on this question. This negative replication in a well-powered study tempers the evidence and is the main reason rs941798 is classified at the moderate evidence level rather than strong. The associations seen in smaller studies may partly reflect population-specific linkage disequilibrium patterns, insufficient statistical power in the replication, or genuine heterogeneity of effect across ancestries.

Practical Actions

For G-allele carriers, the actionable implication is that PTP1B may be relatively more active, blunting insulin and leptin receptor signaling more aggressively. This does not mean diabetes is inevitable, but it does mean the molecular thermostat for insulin sensitivity is set at a less favorable baseline.

Dietary carbohydrate quality matters more for those with impaired insulin signaling: low-glycemic index carbohydrates produce smaller, more sustained glucose excursions that require less compensatory insulin secretion. Reducing refined carbohydrate load lowers the demand on insulin receptor signaling.

Berberine, a plant alkaloid primarily derived from Berberis species, has been shown in multiple clinical trials77 multiple clinical trials to improve insulin sensitivity through multiple mechanisms including AMPK activation. Some research suggests it may also reduce PTP1B expression. At 500 mg twice daily with meals, berberine lowers fasting glucose and HbA1c comparably to metformin in several head-to-head trials.

Fasting glucose and HbA1c monitoring once or twice yearly provides early detection of deteriorating glucose control — actionable before symptoms appear.

Interactions

rs941798 sits in the same metabolic signaling node as TCF7L2 (rs7903146), which governs insulin secretion from beta cells. PTPN1 controls insulin receptor sensitivity; TCF7L2 controls how much insulin is released. Carrying risk alleles at both loci creates a compounded vulnerability: less insulin secreted (TCF7L2) and less effective use of the insulin that is released (PTPN1).

The leptin-signaling connection links rs941798 to appetite regulation. PTP1B terminates both insulin and leptin receptor signaling. Variants in LEP (leptin) or LEPR (leptin receptor) combined with elevated PTPN1 activity could amplify leptin resistance and reduce the effectiveness of satiety signaling.

Nutrient Interactions

dietary carbohydrate altered_metabolism
dietary fat altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal Insulin Signaling Normal

No elevated PTP1B expression; standard insulin receptor sensitivity

The A/A genotype places you on the protective haplotype identified across multiple PTPN1 association studies. The Palmer et al. IRAS Family Study found that protective PTPN1 haplotypes correlated with higher insulin sensitivity index (Si) and lower fasting glucose — the opposite of the risk pattern. Standard dietary and lifestyle approaches for metabolic health apply without the specific genotype-driven modifications relevant to G carriers.

AG One Risk Copy Intermediate

One G allele; modestly elevated PTP1B activity, mild reduction in insulin signaling efficiency

The A/G genotype represents partial tagging of the PTPN1 risk haplotype. PTP1B expression studies suggest a roughly additive (dose-dependent) effect, so one G allele produces intermediate PTP1B upregulation. The practical consequence is that your insulin receptor signaling pathway is shut off slightly faster than in AA individuals, requiring more insulin secretion to achieve equivalent glucose uptake. Over years, this can contribute to insulin resistance if amplified by dietary patterns, sedentary behavior, or obesity. The Bento et al. (2004) data estimated a population-attributable risk of 17-20% for the PTPN1 haplotype block as a whole in Caucasian populations, though the per-allele contribution in heterozygotes is a fraction of this.

GG Two Risk Copies High Risk

Two G alleles; higher PTP1B expression, reduced insulin and leptin receptor sensitivity

The G/G genotype fully tags the PTPN1 risk haplotype. Cheyssac et al. (2006) found that risk-allele homozygotes for the linked rs2426159 had significantly higher systolic blood pressure (p = 0.03) in addition to the lipid and glucose associations seen in dominant-model analyses. Palmer et al. (2004) found that the risk PTPN1 haplotype was associated with lower insulin sensitivity index (p = 0.003) and higher fasting glucose (p < 0.001) in Hispanic Americans across the entire haplotype block — the strongest associations in that study. PTP1B also terminates leptin receptor signaling, so elevated PTP1B expression can compound into reduced leptin sensitivity (requiring higher circulating leptin for equivalent satiety), which may contribute to weight gain over time. The Bento et al. (2004) estimate of OR ~1.3 for the risk haplotype and type 2 diabetes translates to a roughly 30% elevated relative risk, though absolute risk depends heavily on diet, activity, and other genetic factors.